Avibactam

Structural formula
General
Surname	Avibactam
Molecular formula	C 7 H 11 N 3 O 6 S
External identifiers / databases
PubChem	9835049
DrugBank	DB09060
Wikidata	Q15410251
properties
Molar mass	265.24 g mol −1
solubility	soluble in DMSO and DMF (sodium salt)
safety instructions
GHS labeling of hazardous substances Sodium salt danger
H and P phrases	H: 317-334
	P: 261-272-280-285-302 + 352-304 + 340-333 + 313-342 + 311-362 + 364
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Avibactam is a drug that is used as an enhancer for certain antibiotics , but has no antibiotic effect itself. It belongs to the group of β-lactamase inhibitors .

Mode of action

β-lactamase inhibitors inhibit the enzyme β-lactamase produced by the bacteria , with which the bacteria render certain antibiotics from the group of penicillins and cephalosporins ineffective. The production of this enzyme is one mechanism by which bacteria are or can become resistant to these antibiotics. By inhibiting this enzyme, this mechanism of resistance can be circumvented by preventing the bacterial enzyme from destroying the antibiotic.

In contrast to other β-lactamase inhibitors, the covalent bond to the β-lactamase is reversible.

application

Avibactam was approved by the European Medicines Agency on April 28, 2016 only as a combination preparation with ceftazidime in Europe and is marketed by the AstraZeneca company under the trade name Zavicefta®.

According to the approval, avibactam / ceftazidime can be used to treat complicated intra-abdominal infections and infections of the urogenital tract. A study in patients with hospital-acquired pneumonia is ongoing. However, it is hoped that treatment will be successful in diseases of resistant, gram-negative bacteria when other treatment options are not available.

Individual evidence

↑ ^a ^b ^c Cayman Chemical: Avibactam (sodium salt) , accessed December 27, 2019.
↑ SD Lahiri, MR Johnstone et al. a .: Avibactam and Class C β-Lactamases: Mechanism of Inhibition, Conservation of the Binding Pocket, and Implications for Resistance. In: Antimicrobial Agents and Chemotherapy. 58, 2014, p. 5704, doi : 10.1128 / AAC.03057-14 .
^ Pharmaceutical newspaper , accessed December 27, 2019.
↑ EMA approval report , accessed on December 27, 2019.

[caymanchem-1] Cayman Chemical: Avibactam (sodium salt) , accessed December 27, 2019.

[DOI10.1128/AAC.03057-14-2] SD Lahiri, MR Johnstone et al. a .: Avibactam and Class C β-Lactamases: Mechanism of Inhibition, Conservation of the Binding Pocket, and Implications for Resistance. In: Antimicrobial Agents and Chemotherapy. 58, 2014, p. 5704, doi : 10.1128 / AAC.03057-14 .

[3] Pharmaceutical newspaper , accessed December 27, 2019.

[4] EMA approval report , accessed on December 27, 2019.